What Researchers Did
Researchers presented a case report of a 55-year-old woman with delayed radiation myelopathy who was treated sequentially with methylprednisolone and intravenous immune globulin.
What They Found
The patient developed neurological complications 11 months post-radiotherapy, which initially resolved with methylprednisolone pulse therapy. However, residual MRI enhancement prompted intravenous immune globulin (IVIG) administration, leading to the resolution of the lesion enhancement. This suggests IVIG could be a potential therapeutic option for delayed radiation myelopathy activity.
What This Means for Canadian Patients
For Canadian patients experiencing delayed radiation myelopathy, this case suggests that intravenous immune globulin (IVIG) could be considered as a potential treatment option, particularly if initial therapies are insufficient. However, this is a preliminary finding from a single case, and further research is needed before it can be widely recommended.
Canadian Relevance
This study does not have a direct Canadian connection as it was not conducted in Canada, nor did it involve Canadian researchers or patients.
Study Limitations
The primary limitation of this study is its design as a single case report, which limits the generalizability of its findings and lacks a control group for comparison.